Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02212678 · ClinicalTrials.gov registry record · Phase 2
Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
A Phase 2 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02212678 is a Phase 2 study that has completed, run by University of Minnesota. The registered enrollment target is 8 participants.
The verdict
NCT02212678, a Phase 2 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
Interventions
- DRUG N-acetylcysteine capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02212678
The ClinicalTrials.gov registry entry for NCT02212678 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which N-acetylcysteine capsule is the first listed.
NCT02212678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02212678 about?
NCT02212678 is a clinical study titled "Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease". The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.
What is the current status of trial NCT02212678?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2014-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02212678?
The interventions under investigation include: N-acetylcysteine capsule (DRUG).
Who is sponsoring clinical trial NCT02212678?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.